At a Glance
| Indication | Symptomatic dermographism |
| Drug | Remibrutinib |
| Mechanism of Action | Bruton’s tyrosine kinase inhibitor |
| Company | Novartis |
| Trial Phase | Phase III |
| Trial Acronym | RemIND |
| Category | Regulatory Milestone |
| Sub Category | Approval Granted |
| Therapeutic Area | Immunology |
| Regulatory Agency | U.S. Food and Drug Administration (FDA) |
| Approved Market/Region | U.S. |
| Approval Date | October 7, 2026 |
| Patient Population | Adults with symptomatic dermographism inadequately controlled by H1 antihistamines |
| Primary Efficacy Endpoint | Complete response from hives (Total Fric Score) |
| Key Efficacy Data | 29.3% vs 14.0% complete response by Week 12 (p=0.0229) |
| Onset of Response | Week 2 |
| Comparator | Placebo, H1 antihistamines |
| Common Adverse Events | Nasopharyngitis, bleeding, headache, nausea, abdominal pain |
| Other Investigated Indications | Chronic spontaneous urticaria (CSU), Cold urticaria (ColdU), Cholinergic urticaria (CholU), Hidradenitis suppurativa (HS), Food allergy, Relapsing multiple sclerosis (RMS) |
FDA Approves Novartis' Rhapsido for Symptomatic Dermographism
Novartis announced that the U.S. Food and Drug Administration (FDA) approved Rhapsido® (remibrutinib), an oral, highly selective Bruton’s tyrosine kinase inhibitor (BTKi), as the first treatment for adults with symptomatic dermographism (SD) inadequately controlled by H1 antihistamines. This approval is based on data from the Phase III RemIND trial, where 29.3% of patients treated with Rhapsido achieved complete hive resolution by Week 12, compared to 14.0% with placebo (p=0.0229), with responses seen as early as Week 2. Rhapsido demonstrated a safety profile consistent with its use in chronic spontaneous urticaria (CSU), requiring no routine lab monitoring. This milestone expands Rhapsido's utility as the only prescription treatment approved for both CSU and SD when antihistamines alone do not control symptoms.
- The Phase III RemIND trial demonstrated Rhapsido's significant efficacy in symptomatic dermographism (SD), with 29.3% of patients achieving complete hive resolution by Week 12, compared to 14.0% for placebo (p=0.0229). Responses were observed rapidly, as early as Week 2, highlighting its potential to provide quick relief for patients whose chronic hives are triggered by skin friction.
- Rhapsido maintained a consistent and favorable safety profile in SD patients, aligning with observations from its use in chronic spontaneous urticaria (CSU) trials. The most common adverse events were generally mild, including nasopharyngitis, bleeding, headache, nausea, and abdominal pain, with no requirement for routine lab monitoring, which simplifies patient management.
- This FDA approval marks Rhapsido as the first specific treatment for SD and the only prescription medicine approved for both symptomatic dermographism and chronic spontaneous urticaria when H1 antihistamines are insufficient. This expansion offers a crucial new option for over 50% of SD patients who remain symptomatic despite current antihistamine therapy, addressing a significant unmet medical need.
- The approval reinforces the potential of Bruton’s tyrosine kinase (BTK) inhibition across various immune-mediated diseases. Novartis is further investigating remibrutinib in other conditions like hidradenitis suppurativa, food allergy, and relapsing multiple sclerosis, where recent Phase III trials showed positive topline results, indicating a wider therapeutic applicability for this mechanism.
Frequently Asked Questions
What autoimmune disease is linked to dermatographia?
Dermatographia, a form of physical urticaria, is most notably linked to Hashimoto's thyroiditis, an autoimmune disease affecting the thyroid gland. While often idiopathic, its presence can sometimes prompt screening for underlying autoimmune conditions, particularly thyroid dysfunction, given this established association.
Does dermatographia mean you have MCAS?
Dermatographia is a common form of physical urticaria, affecting 2-5% of the population, and is not pathognomonic for Mast Cell Activation Syndrome (MCAS). While it can be a symptom, an MCAS diagnosis requires recurrent multi-systemic symptoms and evidence of mast cell mediator release, fulfilling established diagnostic criteria beyond dermatographia alone.
What causes symptomatic dermatographia?
Symptomatic dermatographia is a form of chronic inducible urticaria characterized by an exaggerated wheal-and-flare response to minor mechanical skin trauma. This reaction is primarily driven by mast cell degranulation and subsequent release of histamine and other inflammatory mediators in the dermis. While often idiopathic, potential triggers or associations can include physical stimuli, stress, certain medications, infections, or underlying systemic conditions, though a definitive external cause is frequently not identified.
How can symptomatic dermographism be treated?
Symptomatic dermographism is primarily managed with non-sedating H1 antihistamines to block histamine release and reduce pruritus and wheal formation. For refractory cases, increasing the dose of H1 antihistamines, combining with H2 blockers, or adding leukotriene receptor antagonists may be considered. Severe, persistent symptoms might warrant systemic therapies such as omalizumab, particularly if it overlaps with chronic spontaneous urticaria. Patients are also advised to avoid physical triggers like friction and pressure.
Will dermographism ever go away?
Dermographism is typically a chronic condition, though its duration is highly variable among individuals. While it can persist for many years, spontaneous remission is possible, with some cases resolving within months and others lasting decades. There is no definitive cure, but symptoms are effectively managed with antihistamines.
How common is symptomatic dermographism?
Symptomatic dermographism is a relatively common form of chronic inducible urticaria. It is estimated to affect approximately 2-5% of the general population, making it the most prevalent type of physical urticaria. While often benign, its chronic nature can significantly impact patients' quality of life.
Contact Us
📍
Address
350 Springfield Avenue,
Suite #200 Summit, NJ 07901
✉️
For General Inquiry
info@pienomial.com
